

# FAK(phospho-Tyr576/Tyr577) Antibody

Catalog No: #11545

Package Size: #11545-1 50ul #11545-2 100ul #11545-4 25ul

Orders: [order@signalwayantibody.com](mailto:order@signalwayantibody.com)Support: [tech@signalwayantibody.com](mailto:tech@signalwayantibody.com)

## Description

Product Name	FAK(phospho-Tyr576/Tyr577) Antibody
Host Species	Rabbit
Clonality	Polyclonal
Purification	Antibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatography using non-phosphopeptide.
Applications	WB IF
Species Reactivity	Human Mouse Rat
Specificity	The antibody detects endogenous level of FAK only when phosphorylated at tyrosine 576/577.
Immunogen Type	Peptide-KLH
Immunogen Description	Peptide sequence around phosphorylation site of tyrosine 576/tyrosine 577 (S-T-Y(p)-Y(p)-K-A) derived from Human FAK.
Target Name	FAK
Modification	Phospho-Tyr576/Tyr577
Other Names	FADK 1; FAK1; PTK2
Accession No.	Swiss-Prot: Q05397NCBI Protein: NP_005598.3
Concentration	1.0mg/ml
Formulation	Supplied at 1.0mg/mL in phosphate buffered saline (without Mg <sup>2+</sup> and Ca <sup>2+</sup> ), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.
Storage	Store at -20°C for long term preservation (recommended). Store at 4°C for short term use.


## Application Details

Predicted MW: 125kd


Western blotting: 1:500~1:1000

Immunofluorescence: 1:100~1:200

## Images



Western blot analysis of extracts from HT29 cells untreated or treated with PMA using FAK(phospho-Tyr576/Tyr577) Antibody #11545.



Immunofluorescence staining of methanol-fixed HeLa cells using FAK(phospho-Tyr576/Tyr577) Antibody #11545.

## Background

Non-receptor protein-tyrosine kinase implicated in signaling pathways involved in cell motility, proliferation and apoptosis. Activated by tyrosine-phosphorylation in response to either integrin clustering induced by cell adhesion or antibody cross-linking, or via G-protein coupled receptor (GPCR) occupancy by ligands such as bombesin or lysophosphatidic acid, or via LDL receptor occupancy. Plays a potential role in oncogenic transformations resulting in increased kinase activity.

Parsons, J.T. et al. (2000) *Oncogene* 19, 5606-5613

Schaller, M.D. et al. (1994) *Mol. Cell. Biol.* 14, 1680-1688.

Cobb, B.S. et al. (1994) *Mol. Cell. Biol.* 14, 147-155.

Chen, H.C. et al. (1996) *J. Biol. Chem.* 271, 26329-26334.

## Published Papers

Jun-shan RUAN, Yu-ping LIU, Lei ZHANG et al., Luteolin reduces the invasive potential of malignant melanoma cells by targeting  $\beta_1\gamma_3$  integrin and the epithelial-mesenchymal transition., *Acta Pharmacologica Sinica.*, 33: 1325-1331(2012)

[PMID:22983392](#)

Note: This product is for in vitro research use only and is not intended for use in humans or animals.